Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption

   Life Technologies Announces Next-Gen Digital PCR Instrument Designed for
                             Widespread Adoption

QuantStudio™ 3D Digital PCR System is latest addition to growing line of
digital qPCR instruments

PR Newswire

CARLSBAD, Calif., Nov. 7, 2012

CARLSBAD, Calif., Nov. 7, 2012 /PRNewswire/ -- Life Technologies Corporation
(NASDAQ: LIFE) today announces the QuantStudio™ 3D Digital PCR System, a
scalable, chip-based instrument that is democratizing this technology for a
rapidly growing market. Featuring a simple workflow with minimal hands-on
time, the benchtop platform is disruptively priced at $30,000 -- enabling
access to a broader community. The system is currently with early access
customers and commercial shipments will begin in the first half of 2013.

Designed with a scalable architecture, the QuantStudio™ 3D Digital PCR
System's first generation chips enable up to 20,000 data points in a single
run -- coverage that satisfies the needs for most digital PCR applications
today. The capacity of future chips will increase exponentially to meet
increasing demands of the research community.

The new platform is the latest addition to agrowing line ofQuantStudio™
digital qPCR instruments from Life Technologies. It complements the
QuantStudio™12KFlex Real-Time PCR System, which the company launched earlier
this year and provides the highestthroughput capability for digital PCR on
the market. 

Considered until recently a niche segment, the digital PCR market is expected
to grow to nearly $250 million globally by 2016. Researchers worldwide use
real-time PCR (polymerase chain reaction) to amplify and quantify nucleic
acids. Digital PCR takes researchers beyond the limits of real-time PCR for
applications that require absolute quantitation of targeted DNA molecules.
Additionally, Life's simple workflow and chip-based platform reduce the risk
of sample contamination and loss of DNA normally associated with droplet-based
systems. The technology is ideal for accurately detecting rare mutations
important in cancer or infectious diseases – the equivalent to finding a
needle in a haystack. It is also increasingly used as a mechanism to perform
quality control experiments on next generation sequencing libraries.

"The QuantStudio™ 3D Digital PCR System is the latest revolutionary platform
from the team that has delivered every market-leading technology in qPCR,"
says Chris Linthwaite, Head of Genetic Analysis, Life Technologies. "By making
this novel platform accessible to all labs, we are enabling the
democratization of digital PCR and helping the scientific community expand the
utilization of this technology in disease research and applications beyond."

Prior to commercial launch, Life Technologies is making the QuantStudio™ 3D
Digital PCR System available to early access users through the Digital PCR
Applications Grant Program, which will fund 20 research projects that
demonstrate innovative applications for the instrument. Five grand prize
winners chosen among the winning proposals will receive a QuantStudio™ 3D
Digital PCR System. For details on submitting a proposal, visit

Life Technologies will host presentations and a poster session from early
access users of the system on Nov. 8 at the American Society of Human Genetics
conference (ASHG). For more information on these talks, visit Life's ASHG
website. The system will be officially unveiled during Explore Art and Science
with Life Technologies, a customer event that will showcase the company's
latest solutions from the Ion Torrent and Genetic Analysis divisions at the
San Francisco Museum of Modern Art on Nov. 7 from 7-10:30 p.m. For invitations
to the event or for more information, visit the Life Technologies booth (#
601) during ASGH.

The QuantStudio™ 3D Digital PCR System is For Research Use Only, not intended
for diagnostic purposes.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied Biosystems®,
Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life
Technologies employs approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of $3.7 billion in 2011. Visit us at our website:

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated
results that involve risks and uncertainties. Some of the information
contained in this press release, including, but not limited to, statements as
to industry trends and Life Technologies' plans, objectives, expectations and
strategy for its business, contains forward-looking statements that are
subject to risks and uncertainties that could cause actual results or events
to differ materially from those expressed or implied by such forward-looking
statements. Any statements that are not statements of historical fact are
forward-looking statements. When used, the words "believe," "plan," "intend,"
"anticipate," "target," "estimate," "expect" and the like, and/or future tense
or conditional constructions ("will," "may," "could," "should," etc.), or
similar expressions, identify certain of these forward-looking statements.
Important factors which could cause actual results to differ materially from
those in the forward-looking statements are detailed in filings made byLife
Technologies with the Securities and Exchange Commission.Life Technologies
undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.


Life Technologies Contact
Mauricio Minotta
760-805-5266 (mobile)

SOURCE Life Technologies

Press spacebar to pause and continue. Press esc to stop.